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Abstract
Background: Development of new peer or lay health-related lifestyle advisor (HRLA) roles is one response to the
need to enhance public engagement in, and improve cost-effectiveness of, health improvement interventions. This
article synthesises evidence on the cost-effectiveness of HRLA interventions aimed at adults in developed countries,
derived from the first systematic review of the effectiveness, cost-effectiveness, equity and acceptability of different
types of HRLA role.
Methods: The best available evidence on the cost-effectiveness of HRLA interventions was obtained using systematic
searches of 20 electronic databases and key journals, as well as searches of the grey literature and the internet.
Interventions were classified according to the primary health behaviour targeted and intervention costs were
estimated where necessary. Lifetime health gains were estimated (in quality-adjusted life years, where possible),
based on evidence of effectiveness of HRLAs in combination with published estimates of the lifetime health gains
resulting from lifestyle changes, and assumptions over relapse. Incremental cost-effectiveness ratios are reported.
Results: Evidence of the cost-effectiveness of HRLAs was identified from 24 trials included in the systematic review.
The interventions were grouped into eight areas. We found little evidence of effectiveness of HRLAs for promotion
of exercise/improved diets. Where HRLAs were effective cost-effectiveness varied considerably: Incremental Cost
effectiveness Ratios were estimated at £6,000 for smoking cessation; £14,000 for a telephone based type 2 diabetes
management; and £250,000 or greater for promotion of mammography attendance and for HIV prevention
amongst drug users. We lacked sufficient evidence to estimate ICERs for breastfeeding promotion and mental
health promotion, or to assess the impact of HRLAs on health inequalities.
Conclusions: Overall, there is limited evidence suggesting that HRLAs are cost-effective in terms of changing
health-related knowledge, behaviours or health outcomes. The evidence that does exist indicates that HRLAs are
only cost-effective when they target behaviours likely to have a large impact on overall health-related quality of
life. Further development of HRLA interventions needs to target specific population health needs where potential
exists for significant improvement, and include rigorous evaluation to ensure that HRLAs provide sufficient value
for money.
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Introduction
Behaviour is recognised as a key determinant of health,
with modifiable lifestyle factors such as smoking, physical
inactivity, poor diet and alcohol consumption, contribut-
ing significantly to morbidity and mortality [1]. This is
particularly the case in developed countries, where these
major health risks tend to be more prevalent amongst the
lower socio-economic groups and therefore contribute to
social inequalities in health [2,3]. Evidence from the UK
indicates that the decline in the proportion of the popula-
tion that engages in unhealthy behaviours has been mainly
in higher socio-economic groups resulting in widening
inequalities [4]. The UK government has responded with
public health policy setting out the action needed to en-
courage and enable individuals to make healthier lifestyle
choices, with a particular focus on those living in socio-
economically disadvantaged areas [5].
Awareness of the role of behavioural factors in health
has increased in the general population in developed
countries, along with a growing chronic disease burden
[6]. Healthcare systems have responded with a shift from
paternalistic to partnership models of care, and sought
to promote increased involvement of patients and the
wider public [7]. The expansion of roles to deliver
health-related lifestyle advice represents one strategy in
this new partnership approach. An example from the
UK is the National Health Service (NHS) health trainer
role, which aims to empower people to adopt healthy
behaviours by offering practical support from someone
who understands the pressures they face [5]. Similar types
of lay or peer-based health-related lifestyle advisor (HRLA)
role have been widely used in many contexts [8-11].
Previous reviews have suggested that HRLAs may be
effective in improving access to health services and ad-
dressing health inequalities, in part by providing cultural
leverage [12,13]. Whilst evidence on cost-effectiveness is
lacking, a perception exists that interventions involving
trained but unqualified peer or lay advisers are cheaper
than those involving health professionals. However, there
are often hidden costs associated with coordination,
training and supervision for these roles [14]. We there-
fore set out to examine systematically the evidence on
the effectiveness of HRLAs and to determine in which
areas they are likely to be cost-effective. Specifically, we
were interested in HLRAs working in the developed
world, where contexts differ significantly from those fa-
cing HRLAs in developing countries and where modifi-
able lifestyle behaviours pose a greater threat to health,
as noted above. The results reported here are part of a
larger evidence synthesis commissioned by the National
Institute for Health Research (NIHR) Health Technology
Assessment (HTA) Programme, which considered both
qualitative and quantitative evidence for the effectiveness,
equity and acceptability of different types of HRLA [15].
Methods
Literature search
Full details of the search for Medline are provided in
Additional file 1 and details of strategies for the other
databases are available from the full report [15]. The lit-
erature searches included a combination of HRLA,
health improvement and methodological terms. The
PICOS (Population, Interventions, Comparators, Out-
comes and Study Designs) framework was used to gen-
erate search terms. Studies were included if they
described interventions that were: delivered in devel-
oped countries by trained but generally unqualified
HRLAs (paid workers or volunteers); consisted of edu-
cation, training, support or counselling aimed at indi-
viduals or groups of peers with the explicit aim of
health improvement; and were iterative (rather than a
one-off event) and delivered in person, by telephone,
post, online or electronically. Studies were excluded if
they described (rather than evaluated) an intervention,
related to acute care or a single episode of advice-
giving, did not have the explicit aim of health improve-
ment, or were not published in English. We also ex-
cluded studies focusing solely on advice or training
delivered to children or adolescents, as there is already
an established literature on peer education for young
people. We included all studies with quantitative data
on relevant interventions rather than restrict the review
to full economic evaluations.
Articles published up to and including September
2008 were searched in the following bibliographic data-
bases: ArticleFirst, ASSIA, British Humanities Index,
Cinahl, DARE, Embase, Francis, IBSS, Medline, NHS
Economic Evaluation Database, PAIS, Psycinfo, Science
Citation Index, Social Science Citation Index, Social Ser-
vices Abstracts, Sociological Abstracts, SIRS researcher,
Web of Knowledge, Worldcat, Zetoc. The search string
was modified in accordance with the functions available
on each database. Grey literaturewas retrieved through
searches using the Google search engine, with the first
100 results retrieved by each search strategy scanned for
relevance; searches of specific websites; and contacting
experts working in the field to request suggestions for
relevant literature. Citation searches of the Science
Citation Index and the Social Science Citation Index
were carried out in order to identify all citations of
those studies assessed as relevant. The reference lists
of papers identified as relevant to the review were
also checked.
Studies were assessed by two reviewers for their met-
hodological rigour based on the Quality Assessment Tool
for Quantitative Studies [16] and included in the review
when they were rated as being of strong or moderate qua-
lity overall. Any disagreement between the reviewers was
resolved through discussion to achieve consensus or,
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where required, review by a third member of the research
team. Full details of the literature search are available in
the published report [15].
Data analysis and synthesis
The disparate nature of the included studies precluded a
meta-analysis of study findings. Instead, evidence on the
effectiveness of HRLAs was assessed based on: i) the
quality and nature of the studies; and ii) the target popu-
lation. Where evidence existed on the cost-effectiveness
of HRLA interventions we evaluated it. Generally this
evidence was lacking and so we synthesised our own es-
timate of cost-effectiveness. We first grouped interven-
tions according to the behaviour targeted as this dictated
the size of the potential health gain. Within groups we
then considered whether the reported interventions used
similar or different modes of delivery. Typical modes of
delivery included: community activities and mailshots
(considered low intensity); telephone and group coun-
selling (low to medium intensity); and personalised
counselling (high intensity). Where studies in the same
target behaviour group used the same mode of delivery,
we selected one study to inform estimates of costs and
effectiveness based on rigor of study design and rele-
vance of the study population. Where interventions
used a different mode of delivery, we compared them as
alternative strategies, either against no intervention, or
against non-HRLA delivered alternatives where these
would be readily available. We ranked interventions ac-
cording to effectiveness and eliminated dominated and
extendedly dominated options prior to calculating in-
cremental cost-effectiveness ratios (ICERs) [17]. The
perspective of included studies was rarely stated, but
none documented costs arising outside of the health
sector. Where we synthesized cost-effectiveness esti-
mates we considered only health benefits and costs
falling on the health sector.
Our method built on previous work which examined
the cost-effectiveness of interventions to incentivise phys-
ician activities which improve patients’ health [18]. This
study recognised that the total cost of such activities in-
clude the cost of the intervention and the impact on
overall health costs of the change in patient health.
Hence the traditional formula for calculating the ICER
can be rewritten to express changes in costs as the sum
of these two components. Few studies report long term
health gains. However, estimates of the long term health
gain from a change in underlying behaviour may be
available. If we assume long term health gains are pro-
portional to the magnitude or extent of behaviour
change the health gain attributable to the intervention
can be expressed as a product of the change in out-
comes measured in patients and the health gain
attributable to a unit change in outcome. The ICER can
then be expressed as:
ICER ¼ ΔC=ΔQ ¼ ΔCi þ ΔCbhð Þ=ΔQ
¼ ΔCi þ ΔCbhð Þ=ΔQbh:ei
where ΔC is the change in overall (health) costs, ΔQ is the
change in outcome attributable to the intervention, ΔCi is
the cost of the intervention, ΔCbh is the overall change in
health care costs from the underlying behaviour change,
ΔQbh is the health gain attributable to a unit change
in behaviour, and ei is the mean proportion or degree
of change achieved by the intervention population.
We determined ei from the primary outcome reported
in each study. These were typically changes in behaviour
(such as mammography attendance) or in physiological
markers (such as HbA1c concentration). We assessed
assumptions underpinning analysis in each study and
substituted conservative results where assumptions may
have been generous (e.g. we assumed smoking cessation
participants lost to follow up had resumed smoking).
We searched the published literature for modelling studies
reporting the lifetime health gains in Quality Adjusted Life
Years [19] (QALYs) (ΔQbh) and health care cost impacts
(ΔCbh) attributable to changes in behaviour or associated
with changes in physiological health markers. Where more
than one modelling study was available we selected the
study based on quality and applicability to a UK context.
Intervention costs (ΔCi) were taken from cost data re-
ported in the studies reviewed, where these were available.
Costs in foreign currency were converted to UK pounds
and inflated to 2008 prices. In the absence of cost data we
estimated programme costs. We estimated the total staff
time to deliver an intervention, and applied a unit cost
which included training and overheads from an authorita-
tive UK source (Unit Costs of Health and Social Care) for
an occupation that most closely matched the activity
described in the intervention [20]. Details of the costs
estimations are given in Additional file 1.
Little evidence is available on long-term recidivism for
lifestyle change interventions [21,22]. The exception to
this is smoking cessation, where recidivism is substantial
[23]. Seven year follow-up of participants in a lifestyle
intervention for diabetes management showed that the
majority had relapsed [24]. We assumed that interven-
tions would be repeated in the third, sixth and tenth
year after the initial intervention, and that despite this
50% of participants achieving change at follow-up would
subsequently relapse gaining no health benefits. Costs
for implementing the intervention in years three, six and
ten were added to the implementation costs in the first
year after discounting at 3.5% per annum to estimate the
total cost of the intervention. We did not assume that
smoking cessation interventions would be repeated;
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instead, we assumed that 75% of abstainers after three
months would subsequently relapse based on data from
1990 California Tobacco Survey [25]. We did not assume
that HIV prevention work amongst drug users would be
repeated in subsequent years, given the transient nature of
the population; instead, we applied conventional, conser-
vative assumptions that intervention effects lasted for the
duration of observation only.
Where estimated ICERs were likely to be sensitive to
assumptions around health gains or recidivism, we tested
these assumptions in sensitivity analysis.
Results
After quality appraisal 24 met the inclusion criteria for
the review. Figure 1 illustrates the search results and
screening process.
Interventions included in the review were grouped into
eight health areas: general chronic disease management;
management of type 2 diabetes; promotion of smoking
cessation; breast cancer screening; prevention of HIV in-
fection; healthy diet and/or physical activity; breastfeeding;
and mental health. Each of these areas is described in
detail below.
General chronic disease management
Five studies were reviewed on the subject of lay-led dis-
ease management for a range of chronic conditions
[26-30]. Three of these [26-28] were conducted in the
UK, including an evaluation of the national Expert Pa-
tients Programme [26]. All of the studies reported sig-
nificant improvements in patient self-efficacy and self
care behaviour attributable to the intervention. Barlow
Foreign language n = 2
Quantitative studies included 
in this article
n=24
Titles identified and screened
n = 22898
Excluded n = 22517
Unable to obtain/further
information required to make
assessment n = 37
Full copies retrieved and 
accessed for eligibility
n = 381
Excluded n = 282
Study design / descriptive 
material n = 113 (40.1%)
Reviews n = 24 (8.5%)
Age group (i.e. under 18 
years old) n = 25 (8.9%)
Not health improvement as 
primary aim n = 48 (17.0%) 
Lack of trained interventionist 
n = 7 (2.5%)
Basic information (i.e. online 
support groups) n = 3 (1.1%)
Delivered by professional staff 
n = 62 (22.0%)
Grey literature
n = 209
Google searches 
(including online 
reference lists)
n = 15
Studies identified from 
contact with experts
n = 12
Relevant studies from 
included reviews
n = 182
Publications meeting the 
inclusion criteria
n = 269
Publications Quality Assessed 
as weak / moderate
n=243
Publications Quality Assessed 
as strong / included in review
n = 26 Qualitative studies excluded 
from this article
n=2
Figure 1 Flowchart showing study selection process.
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et al. [27] demonstrated statistically significant improve-
ments in anxiety and depression. Kennedy et al. [26] re-
ported improvements in physical health, Lorig et al.
(2003) [29] found significant improvements in pain, and
both studies reported improvements in psychological
wellbeing and health distress. There was some evidence
that health improvements were maintained over time.
The extent to which improvements in self-efficacy and
symptom management translate into gains in health-
related quality of life (HRQoL) is unclear, although the
impact of chronic diseases on HRQoL is likely to be
considerable.
Evidence of the impact of interventions on health care
utilisation was inconsistent. Kennedy et al. [26] reported
reductions in both primary and secondary care attribut-
able to the intervention. The differences were not statis-
tically significant, but a reduction in inpatient days in
the intervention arm was sufficient to offset the inter-
vention cost. Griffiths et al. [28] and Barlow et al. [27]
found no impact on health care utilisation attributable
to the intervention. Lorig et al. (1999) [30] found a re-
duction in inpatient days but no reduction in primary
care. Lorig et al. (2003) [29] found a reduction in pri-
mary care and emergency admissions, but no change in
inpatient days.
Estimating cost-effectiveness
Richardson et al. undertook a cost-effectiveness analysis
of the Expert Patients Programme, and reported a 94%
probability that it was cost-effective at a threshold of
£20,000 per QALY [31]. This analysis appears to be ro-
bust, but may lack generalizability. Most of the interven-
tion costs (£250 per patient) were offset by reductions in
inpatient days, attributable to a few resource-intensive
patients. Evidence from the other studies of the impact
on secondary care is mixed. Nevertheless, the chronic
disease management programmes offer the possibility of
enabling patient empowerment at modest or zero overall
cost.
Management of type 2 diabetes
Three studies reported different methods of delivering
lay-led lifestyle and disease management advice to poor,
urban patients with diabetes [32-34]. Young et al. [32]
describes a low intensity telephone counselling interven-
tion, Gary et al. [33] reports a group counselling inter-
vention delivered by promotoras (a term for lay health
advisers used by Spanish-speaking communities) and
Lujan et al. [34] reports an individual counselling inter-
vention. We analysed each intervention as an alternative
approach to promoting diabetes disease management in
marginalised populations. Change in HbA1c concentra-
tion, a well-recognised physiological marker of diabetes
control [35], was the primary outcome of each inter-
vention. All three studies reported falls in HbA1c levels
of similar magnitude attributable to the intervention:
0.25% (95% CI 0.08 to 0.73) in Lujan et al.; 0.31% (95%
CI 0.11 to 0.52) in Young et al.; and 0.30% (CI −0.18 to
0.78) in Gary et al. The cost of the telephone-based
intervention in Young et al. (£258 per participant) is re-
ported separately [36]. We estimated costs per partici-
pant of £757 and £988 for Gary et al. and Lujan et al.
respectively. On the basis of these costs the telephone
counselling intervention dominates the other two (it is
cheaper and more effective). However, differences in base-
line HbA1c between intervention and control in Lujan
et al. may have diminished the observed treatment effect
through regression to the mean. Consequently, we applied
a favourable assumption that the treatment effect in Lujan
et al. is the fall in HbA1c in the treatment arm between
baseline and follow-up (0.45%).
Estimating cost-effectiveness
We assumed a linear relationship between changes in
HbA1c concentration and the resulting impact on health
gains and costs. A number of studies have estimated the
health gain in QALYs from improved control of HbA1c
[37-42]. We applied a value of 0.38 QALYs per 1% fall in
HbA1c concentration taken from the Center for Out-
comes Research (CORE) diabetes model [37]. Estimates
of the costs saved from a fall in HbA1c levels in a UK
setting were taken from the Diabforecaster model (£686
2008 GBP for a fall from 8.0% to 7.0%) [38]. In the base
case analysis, the ICER for the telephone counselling
intervention in Young et al. was £13,600. The commu-
nity health worker intervention in Gary et al. is domi-
nated by the telephone counselling intervention. The
ICER for the promotora intervention in Lujan et al. is
£94,500.
In a sensitivity analysis the number of patients who re-
lapse (and gain no health improvement) was varied be-
tween 25% and 75%. This is mathematically equivalent
to assuming a QALY gain from HbA1c control of plus
or minus 50% (0.19 and 0.57 QALYs). The resulting
ICER for Young et al. varied from £8,400 to £28,800,
and the ICER for Gary et al. varied from £62,400 to
£191,000. Hence, the conclusion that a low intensity
intervention for the management of type 2 diabetes is
cost-effective at thresholds acceptable in the UKis robust
to variation in health gains or recidivism.
An additional study estimated an ICER at £43,400 for
the intervention described in Young et al. and concluded
that the intervention was not cost-effective [36]. The
analysis used data from the Centers for Disease Control
type 2 diabetes model, in which US style intensive man-
agement of HbA1c levels generate considerable additional
health care costs from a fall in HbA1c [39]. Under UK
practice style, the estimated overall health care costs
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attributable to a fall in HbA1c levels are negative, which
would greatly reduce the ICER for the intervention in
Young 2005.
Smoking cessation
Four reviewed studies focused on advice or counselling
regarding smoking cessation [43-46]. The evidence in
May et al. [43] suggests that a ‘buddy system’ based on
mutual support is not effective. The population in
Emmons et al. were cancer survivors which limits the
generalizability of the study [44]. The population in
Woodruff et al. [45] appears representative of individual,
ethnically-targeted smoking cessation services. Conse-
quently, we considered this intervention, and assumed a
three month quit rate of 17.4% based on the intention-
to-treat analysis rather than the primary results (which
ignored those lost to follow-up). We estimated the cost
of the intervention at £215 per participant.
Estimates of the average QALY gain for cessation from
smoking by Fiscella and Franks [47], and Cromwell [48]
concur (1.98 and 1.97 QALYs respectively), although re-
cent evidence [49] would suggest both are conservative.
Health care costs related to smoking are considerable
[50]. The impact of smoking cessation on health care
costs unrelated to smoking is less well established, but
these will inevitably rise with increased longevity and
may outweigh the direct cost savings [51]. We applied a
conservative assumption that the overall cost savings
were zero. We assumed that 50% of three-month ab-
stainers would have relapsed at one year and that 50% of
one-year abstainers would subsequently relapse, with all
those who relapse gaining no health benefits. Hence 25%
of three-month quitters were assumed to have quit per-
manently, gaining 1.97 QALYs each.
Estimating cost-effectiveness
We compared the HRLA intervention, to reasonable al-
ternatives available. We assumed that 3% of smokers
who wish to stop are successful without seeking profes-
sional support [52]. The success rate of brief advice in
conjunction with Nicotine Replacement Therapy or
Buproprion was estimated at 4%, [53] with an estimated
cost of £47 [54]. Pharmacy-based smoking cessation ser-
vices were assumed to deliver a 5% quit rate at £55 per
participant [55]. We assumed an annual success rate of
10% for smokers’ clinics and costs per participant of
£350 [55].
Cost-effectiveness calculations are presented in Table 1.
The data indicate that smokers’ clinics are more effective
than individual counselling from HRLAs, although costs
are similar. Smokers’ clinics are cost-effective and the
preferred option. However, this intensive group-based
therapy may not appeal to many smokers. Tailoring ser-
vices to smokers’ choices is likely to boost motivation
and resulting quit rates. Hence, HRLA interventions
might be cost-effective as an alternative service. Com-
pared with willpower alone, the ICER for smoking cessa-
tion advice delivered by HRLAs is £3800.
Mammography promotion
Four studies evaluated HRLA interventions to promote
breast cancer screening (mammography) [56-59]. Three
studies [56-58] targeted broadly similar populations of
poor, rural women, whereas the fourth [59] targeted re-
cent immigrants to the US. The likelihood of specific
barriers to mammography in non-native language speak-
ing communities limits the generalizability of the latter
study. Hence we considered two types of intervention: a
low intensity intervention focusing on community events
and mass mailshots as described in Andersen et al. [56],
and a high intensity intervention based primarily on in-
dividual counselling as described by Earp et al. [57] and
Paskett et al. [58] The treatment effect (2.5% uptake)
and costs ($34 per participant, £34 2008 GBP) reported
for the community arm in Andersen et al. were assumed
for the low intensity intervention, and the treatment ef-
fect (15.2% uptake) and costs ($730 per participant, £657
2008 GBP) reported in Paskett et al. for the high inten-
sity intervention.
A number of authors have modelled the cost-effectiveness
of mammography to determine the optimum screening
frequency/age range [60-65]. Recent modelling studies
have reported lifetime benefits of mammography in the
range 0.0324–0.0386 QALYs for biennial or triennial
screening [60-62]. We used the estimate of 0.0386
Table 1 Cost-effectiveness calculations for various smoking cessation options
Cost (£) Annual quit rate QALY gain Incremental gain (QALYs) Incremental cost (£) ICER
Willpower alone 0 3% 0.0295 - - -
Brief advice 47 4% 0.0396 0.0099 47 Extendedly dominated
Pharmacy services 55 5% 0.0495 0.0099 8 £2,800
Tailored HRLA counselling 215 8.7% 0.0857 0.0364 160 £4,400
Smokers’ clinics 350 10% 0.0985 0.0128 135 £10,500
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QALYs from Rojnik et al. [60] which is generous, and
matches UK screening policy (triennial from 50 to 70
years of age). Overall health care costs from mammog-
raphy of €191 (£148 2008 GBP) were taken from the
same study.
Estimating cost-effectiveness
The ICER for the low-intensity intervention was
£251,000 and the ICER for the higher intensity interven-
tion was £896,000. Sensitivity analysis assuming 0%
relapse without repeating the HRLA intervention gener-
ated an ICER for the low intensity intervention of
£39,000. Andersen et al. [56] reports a cost-effectiveness
analysis of the community activity intervention, giving a
cost per life-year saved of US$56,000 (1995 US$) or
£56,000 (2008 GBP). Description of the analysis is scant
and no mention is made of any allowance for recidivism.
Nevertheless, the analysis supports the conclusion that
the HRLA intervention would not be considered cost-
effective in the UK.
HIV prevention
Two reviewed studies describe the training of illegal
drug users to deliver HIV prevention messages, primar-
ily promoting condom use and the sterilisation of drug
injection equipment [66,67]. Whilst both studies are
mainly qualitative, quantitative data on each interven-
tion has also been published [68,69]. The two inter-
ventions are similar, but Dickson-Gomez et al. (2003)
[66] included a control group who received an appro-
priate comparison intervention, and therefore analysis
was based on that study. The study reports reduction
in both risky sexual and injection behaviours. However,
an ordinal scale was used to define the magnitude of
risky behaviours obfuscating the absolute reduction fol-
lowing the intervention, and the authors elected to ig-
nore any reported increases in risky behaviour which
may have biased results.
Estimating cost-effectiveness
Data in Latkin et al. indicates the intervention was more
effective in reducing needle-sharing than unsafe sex [68].
We considered only the impact of reductions in needle-
sharing given that the risk of infection from shared
needles is higher than from unprotected vaginal sex
(although not unprotected anal sex) [70]. We based esti-
mates of infections avoided on a Bernoulli-process
model of transmission, where probability of infection is
a function of the number of unsafe acts, the risk of
transmission from an unsafe act, and the general preva-
lence of disease (equation 1 below) [71]. We applied the
standard assumptions that the observed reduction in risk
behaviour occurs only for the duration of the interven-
tion, and that persons prevented from infection are not
subsequently infected.
Probability of infection P
¼ 1 ‐ 1‐πð Þ þ π 1 − ad⋅aið Þð Þf gn ð1Þ
where π = HIV prevalence
αd = risk of infection of needle used by sero-positive
user = 0.9 [72].
αi = risk of infection from infected needle = 0.0067 [73].
n = number of incidences of needle sharing
We considered a London setting where increased HIV
prevalence of 4% [74] amongst drug users would render
the programme more effective than in the rest of England
(prevalence 0.6% [75]). We estimated 0.00722 cases of
HIV infection avoided for the intervention and 0.00288
for the control, an incremental gain from the intervention
of 0.004332 cases averted (details in Additional file 1).
We assumed that averting one case of HIV infection
avoided £143,000 [76] and generated a health gain of
around 5.37 QALYs [77]. On that basis, the intervention
saves £619 and generates 0.0233 QALYs compared to
the control, or £1,032 and 0.0388 QALYs compared to
no intervention. Total intervention costs were estimated
at £59,200. The resulting ICER for the HRLA programme
is (59,200 - 619)/0.0233 = £2,514,000 per QALY compared
to the control, and (59,200 – 1032)/0.0388 = £1,499,000
compared to no intervention.
Diet and physical activity
Five studies evaluated an intervention aiming to improve
diet and exercise levels in a marginalised community
using culturally tailored approaches [78-82]. Keyserling
et al. [78] described an intervention for women with dia-
betes, while the four other studies [79-82] were aimed at
healthy adults. Each intervention involved community
health workers or promotoras delivering individual
counselling and advice with the goal of increasing exer-
cise and/or improving diets.
The evidence of improvements in diet, based on self-
reported intake, is undermined by evidence of under-
reporting of consumption. There is evidence of improvement
in fat intake and fruit and vegetable consumption, but
studies measuring weight showed no change. Physiological
evidence reported in Staten et al. is mixed [79]. Keyserling
et al. reports no improvements in HbA1c levels despite
extensive health advice and counselling [78]. The evidence
of unreliability of self-reported dietary intake might also
lead us to doubt the self-reported evidence of increased
physical activity. Elder 2006 reports that improvements
from the intervention observed at three months dissipated
at six and 12-month follow-up [80].
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Overall, the physiological data conflict with the self-
reported improvements in diet or exercise, and there is
evidence that any possible changes are not sustained.
These results suggest that individual counselling from
HRLAs is ineffective at achieving long-term changes in
diet or exercise patterns. Consequently, these interven-
tions do not appear to be cost-effective.
Breastfeeding
Two studies concerned breastfeeding: the study by Dennis
et al. [83] took place in Canada in circumstances similar
to a UK context, while the study by Morrow et al. [84]
was conducted in Mexico. The Canadian intervention uti-
lised telephone support from a woman experienced with
breastfeeding, in addition to standard practice. The study
reported risk ratios at four, eight and 12 weeks for in-
creased breastfeeding attributable to the programme. The
risk ratio at six weeks was estimated at 1.12 (95% confi-
dence interval: 1.01 – 2.00) using regression and com-
bined with UK data on breastfeeding [85] to estimate the
peer support programme could increase breastfeeding at
six weeks in the UK from 48% to 54%.
Reported benefits of breastfeeding include gains in
Intelligence Quotient [86] and reductions in obesity [87]
and childhood type 1 diabetes [88]. We did not, however,
find any studies estimating a gain in QALYs from breast-
feeding. Consequently, we could not estimate an ICER for
the HRLA intervention described in Dennis et al.
Mental health promotion
Only one study was identified that addressed mental
health issues [89]. The intervention involved an experi-
enced parent providing support to families of children
with selected chronic diseases. The control group were
given a telephone number through which they could ac-
cess the HRLA, but only two mothers called the number,
suggesting selective demoralisation occurred in the con-
trol arm.
The study reported a statistically significant improve-
ment in anxiety levels of 2.1 points on the Psychiatric
Symptom Index (range 0 to 100) [90] attributable to the
intervention. Costs were not reported but the interven-
tion consumed ten hours of contact time plus telephone
support from paid peer advisers, in addition to support
from a clinical specialist. Hence costs were likely to be
large. We found insufficient evidence in the literature to
attach a QALY gain to reductions in anxiety. Hence, we
did not calculate an ICER. The change in anxiety ap-
pears to be modest and the comparator used in the trial
may have biased this estimate. Given the resource inten-
sive nature of the intervention it is unlikely to be cost-
effective.
Discussion
Main findings of this study
Our analysis suggests that peer- or lay-delivered smok-
ing cessation interventions are highly cost-effective com-
pared to no intervention. Whilst smokers’ clinics are
more cost-effective they may not be accessed by margin-
alised groups. Promotion of uptake of mammography,
exercise and healthy eating, or HIV prevention activities
by HRLAs are not cost-effective. Programmes directed
towards improved chronic disease management have the
potential to be cost-effective, particularly for patients
with type 2 diabetes. The conclusions on physical acti-
vity and healthy eating flow from a lack of evidence of
effectiveness in these areas. Where there is evidence of
effectiveness, lay health advisers are not always cost-
effective. The key driver is the size of the potential
health gain from the behaviour promoted. This is large
for smoking cessation, and justifies a relatively intensive
intervention. The gain from mammography, recently es-
timated to be an additional 9.2 days life expectancy [91],
is simply insufficient to justify even a low intensity pro-
motion programme. The benefits from improved ma-
nagement of diabetes are potentially large, and may
justify a low intensity intervention. Whilst the benefit of
averting HIV infection is large, the health gain from re-
ducing needle-sharing is modest, and consequently HIV
risk reduction programmes are unlikely to be cost-
effective in the UK. We were unable to link evidence of
effectiveness of HRLA interventions in mental health
and breastfeeding promotion with changes in HRQoL.
Strengths and limitations of this study
This analysis is based on the first systematic review of
the diverse range of HRLA roles to be found in deve-
loped countries [15]. The review was comprehensive
both in its scope and in the focus on acceptability, ef-
fectiveness and cost-effectiveness of interventions.
Nevertheless, we found few studies assessing outcomes
after one year. Restrictions on inclusion by study design
and quality assessment excluded many weaker studies.
The remaining studies were predominantly single focus
interventions, with defined and often standardised pro-
tocols, and a predominant focus on individual behaviour
change rather than community development. The small
number of studies reviewed in each area raises the possi-
bility of publication bias leading to an over-estimate of
the effectiveness of HRLA programmes. We lacked suffi-
cient evidence to determine whether any of the interven-
tions reduced or widened health inequalities. However,
effective interventions targeted at marginalised commu-
nities are likely to reduce the socio-economic gradient in
unhealthy behaviours.
The benefits of lifestyle interventions are typically ac-
crued decades into the future for younger people, hence
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capturing long term outcomes is challenging. Conse-
quently, we had to model long term impact from surrogate
short term outcomes which raises concerns about whether
the observed behaviour changes were maintained. In the
absence of evidence we applied conservative assumptions
on the maintenance of behaviour changes rather than sim-
ply assuming that no relapse occurred. Nevertheless, our
conclusions on mammography promotion were robust to
the very generous assumption, commonly applied, that in-
creased adherence is maintained for life. Data on long
term maintenance would greatly improve the quality of
evaluations of health promotion programmes. We also se-
lected conservative estimates of the health gain from life-
style changes with regard to our resulting inference – high
estimates for mammography and low estimates for smok-
ing cessation – and we explored the impact of changing
assumptions with sensitivity analysis. Inferences around
mammography promotion and management of type 2
diabetes were robust to this analysis.
Interpretation of findings and relationship to existing
knowledge
Few studies have evaluated the cost-effectiveness of HRLA
interventions. Of the three studies we found which did,
[31,36,56] two had methodological weaknesses [36,56].
Andersen et al. appear to make the commonly applied but
unrealistic assumption that behaviour change observed
during follow-up is maintained for life [56]. In contrast,
assumptions of cost increases from improved manage-
ment of type 2 diabetes made by Mason et al. in the evalu-
ation of the telephone based counselling intervention
appear unrealistic [36]. We drew on the approach of
Mason et al., but sought to apply the most appropriate es-
timates of the costs and effects of behaviour changes along
with more realistic assumptions on adherence. With the
exception of smoking cessation, there was very little evi-
dence to guide assumptions on adherence and so we
tested our assumptions in sensitivity analysis. This study is
the first to evaluate the cost-effectiveness of HRLA inter-
ventions across a diverse range of health behaviours using
the same methodology and applying conservative assump-
tions on adherence. The results indicate that HRLAs can
be cost-effective when they target behaviours associated
with significant detriments to health.
Conclusion and implications
Cost-effectiveness of HRLAs are strongly influenced by
the size of the health gain from the lifestyle changes tar-
geted. For example, lifetime adherence to mammography
screening yields health gains of around 0.04 QALYs
compared to 0.4 QALYs for a person with type 2 dia-
betes reducing their glycosylated haemoglobin by 1%,
and 2.0 QALYs for smoking cessation. Consequently the
potential health gains from interventions that promote
mammography are small compared to those promoting
smoking cessation. HRLAs are likely to be most profit-
ably employed delivering interventions with the potential
to generate large health gains. They are unlikely to be
cost-effective when targeting behaviours with only very
modest potential to increase expected HRQoL (such as at-
tendance at mammographic screening). Further research
on adherence to short term behaviour changes might fa-
cilitate more informed assumptions on the long term
maintenance of behaviour changes which underpin esti-
mates of the cost-effectiveness of interventions aimed at
improving unhealthy lifestyles.
Additional file
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